First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers
Background Inhibition of the epithelial sodium channel (ENaC) represents a mutation-agnostic therapeutic approach to restore airway surface liquid hydration and mucociliary clearance in patients with cystic fibrosis. BI 1265162 is an inhaled ENaC inhibitor with demonstrated preclinical efficacy. Met...
Main Authors: | Alison Mackie, Juliane Rascher, Marion Schmid, Verena Endriss, Tobias Brand, Wolfgang Seibold |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2021-02-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/7/1/00447-2020.full |
Similar Items
-
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
by: Peter Nickolaus, et al.
Published: (2020-12-01) -
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1
by: Christopher H. Goss, et al.
Published: (2020-12-01) -
Safety assessment of inhaled xylitol in mice and healthy volunteers
by: Kline Joel N, et al.
Published: (2004-09-01) -
Pulmonary clearance of inhaled particles in human volunteers and laboratory animals
by: Bailey, M. R.
Published: (1983) -
Effect of Amoxicillin And Cefalexin on The Pharmacokinetics of Diclofenac Sodium in Healthy Volunteers
by: Shaima M. Ali, et al.
Published: (2015-06-01)